These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15815665)

  • 21. Biotech boom.
    Jayaraman KS
    Nature; 2005 Jul; 436(7050):480-3. PubMed ID: 16049469
    [No Abstract]   [Full Text] [Related]  

  • 22. Profiles of four top biotech companies in India.
    Suresh N; Rao ChS
    Biotechnol J; 2009 Mar; 4(3):295-300. PubMed ID: 19296435
    [No Abstract]   [Full Text] [Related]  

  • 23. Public biotech 2008--the numbers.
    Huggett B; Hodgson J; Lähteenmäki R
    Nat Biotechnol; 2009 Aug; 27(8):710-21. PubMed ID: 19668175
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biotech drugs come of age; policymakers take notice.
    Iglehart JK
    Health Aff (Millwood); 2006; 25(5):1202-3. PubMed ID: 16966714
    [No Abstract]   [Full Text] [Related]  

  • 26. Biotech business Down Under.
    Beckley C
    Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
    [No Abstract]   [Full Text] [Related]  

  • 27. Biotech round the world: focus on Canada.
    Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
    [No Abstract]   [Full Text] [Related]  

  • 28. US biodefense contracts continue to lure biotechs.
    Shaffer C
    Nat Biotechnol; 2010 Mar; 28(3):187-8. PubMed ID: 20212465
    [No Abstract]   [Full Text] [Related]  

  • 29. Innovation drives success in Switzerland's biotech scene.
    Whyte B
    Drug Discov Today; 2005 Oct; 10(20):1342-5. PubMed ID: 16253869
    [No Abstract]   [Full Text] [Related]  

  • 30. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 25 breakout companies--biotech: Crucell.
    Stipp D
    Fortune; 2005 May; 151(10):155, 158. PubMed ID: 15931764
    [No Abstract]   [Full Text] [Related]  

  • 32. The commercialization of biotechnology in Japan.
    Müller C; Fujiwara T
    Drug Discov Today; 2002 Jul; 7(13):699-704. PubMed ID: 12110222
    [No Abstract]   [Full Text] [Related]  

  • 33. Perspective: Biotech funding trends: Insights from entrepreneurs and investors.
    Gruber AC
    Biotechnol J; 2009 Aug; 4(8):1102-5. PubMed ID: 19685460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Niche indications could drive higher valuations.
    Ransom J
    Nat Biotechnol; 2006 Dec; 24(12):1457. PubMed ID: 17160028
    [No Abstract]   [Full Text] [Related]  

  • 35. Biotechnology in Ireland: hard work, money and the brain gain.
    O'Neill MF
    Drug Discov Today; 2007 Feb; 12(3-4):108-11. PubMed ID: 17275730
    [No Abstract]   [Full Text] [Related]  

  • 36. Swooping for biotech.
    Wadman M
    Nature; 2005 Sep; 437(7058):475. PubMed ID: 16177760
    [No Abstract]   [Full Text] [Related]  

  • 37. How the street sees biotech.
    Lashinsky A
    Fortune; 2003 Jun; 147(11):86. PubMed ID: 12800576
    [No Abstract]   [Full Text] [Related]  

  • 38. Calculating the value & risk in licensing deals. 20-21 November 2002, Brussels, Belgium.
    Contrafouris Y
    IDrugs; 2003 Jan; 6(1):21-2. PubMed ID: 12838965
    [No Abstract]   [Full Text] [Related]  

  • 39. Nasdaq restructures biotech index.
    Morrison C
    Nat Biotechnol; 2001 Mar; 19(3):187. PubMed ID: 11231518
    [No Abstract]   [Full Text] [Related]  

  • 40. Sanofi Aventis grooms its ranks for biotech partnering.
    Moran N
    Nat Biotechnol; 2009 Jul; 27(7):581-2. PubMed ID: 19587645
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.